Investing Merck: Monupilavir Could be Game Changer by admin October 4, 2021 October 4, 2021 Merck & Firm (MRK) gained over 8% to shut at $81.40 on October 1. Merck is a biopharmaceutical agency whose essential product is the PD-L1 inhibitor Keytruda, which treats melanoma.… Read more 0 FacebookTwitterPinterestEmail